Wilson Sonsini Goodrich & Rosati has advised Sidewinder Therapeutics. Sidewinder Therapeutics, a biopharmaceutical company focused on next-generation bispecific antibody-drug conjugates (ADCs) for cancer treatment, announced the...
Sidewinder Therapeutics Secures $137 Million in Series B Financing to Advance Bispecific ADC Programs
UCB Acquires Neurona Therapeutics in $1.15 Billion Deal
Covington has advised UCB. Wilson Sonsini Goodrich & Rosati has advised Neurona Therapeutics. UCB, a global biopharmaceutical company, has entered into a definitive agreement to acquire...
Stately Bio’s $12 Million Seed Financing Round
Wilson Sonsini Goodrich & Rosati advised Stately Bio on the transaction. Stately Bio, a start-up developing cell therapies using an ML-powered live-cell imaging platform, emerged from...
Synthetic Design Lab’s $20 Million Seed Funding Round
Wilson Sonsini Goodrich & Rosati advised Synthetic Design Lab on the transaction. Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic...
Neurona Therapeutics’ $102 Million Oversubscribed Financing Round
Wilson Sonsini Goodrich & Rosati advised Neurona Therapeutics on the transaction. Neurona Therapeutics (Neurona), a clinical-stage, privately-held, biotherapeutics company developing regenerative cell therapies for disorders of...
Dren Bio’s Collaboration with Novartis
Wilson Sonsini Goodrich & Rosati advised Dren Bio on the transaction. Dren Bio, Inc., a privately held, clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune,...
Neurona Therapeutics’ $120 Million Financing
Wilson Sonsini Goodrich & Rosati advised Neurona Therapeutics on the transaction. Neurona Therapeutics announced it closed a $120 million financing co-led by Viking Global Investors and Cormorant...
Pyxis Oncology’s Acquisition of Apexigen
Sidley Austin LLP advised Pyxis Oncology, Inc. on the transaction, while Wilson Sonsini advised Apexigen on the transaction. Pyxis Oncology, Inc., a clinical-stage company, and Apexigen,...
Apexigen’s Business Combination Agreement with Brookline Capital Acquisition Corp.
Wilson Sonsini advised Apexigen on the deal. Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology,...